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Abstract
This study was carried out to determine whether an extracorporeal membrane oxygenation
(ECMO) support could be sufficiently conducted by the right ventricle alone from the viewpoint
of the hemodynamics and blood gas state. Six infant dogs underwent a bypass between the left
pulmonary artery and left atrium with an in-line oxygenator after a left pneumonectomy. Par-
tial ECMO support was conducted simply by opening the circuit, and total ECMO support was
conducted by ligating the right pulmonary artery. After the establishment of partial ECMO, ap-
proximately one-third of the right ventricular output was passively shunted through the bypass
circuit, and the cardiac index and central venous pressure did not change. The mean pulmonary
arterial pressures increased significantly. After a complete ligation of the right pulmonary artery,
all 6 dogs survived for 12 h, but the cardiac output and blood pressure decreased significantly.
The blood gas state was sufficiently maintained throughout the experiment. The results suggest
the possibility of using the pumpless ECMO support. However, the flow resistance of the mem-
brane oxygenator proved to still be too high for use in a total pumpless ECMO. Further studies
on long-term ECMO and the development of a membrane oxygenator with a considerably low
flow-resistance are needed.
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he only current treatment for end-stage pulmo-
nary diseases is a lung or heart-lung transplan-
tation,  with the major limitation of transplantation 
being a shortage of organ donors [1,  2]. 
Extracorporeal life support techniques are commonly 
used today to treat patients with severe respiratory 
and/or cardiac failure [3].  The device,  however,  is 
so large that the patient is unable to carry out his/
her normal daily activities.  It has been suggested in 
several reports that a pumpless implantable artiﬁ cial 
lung could conceivably be useful not only as a bridge 
to lung transplantation,  but also as a means of pul-
monary support for patients with acute respiratory 
failure [4,  5].  We thought that the limitation of 
daily activities for such patients could be improved 
by means of a pumpless implantable artiﬁ cial lung 
placed between the right heart and the left heart if a 
membrane oxygenator can be suﬃ  ciently perfused by 
the native right ventricle (RV) alone with an appro-
priate gas exchange.
　　The purpose of the present study was to deter-
mine whether an extracorporeal membrane oxygen-
aton (ECMO) system placed between the left pulmo-
nary artery (PA) and left atrium (LA) of the heart 
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could be perfused by RV alone,  and also to evaluate 
the eﬀ ectiveness of a pumpless ECMO support from 
the viewpoint of the hemodynamics and blood gas 
state in an experimental canine model.
Materials and Methods
　　Artiﬁ cial lung. 　A commercially available 
extracapillary-perfusion membrane oxygenator 
9.8 × 5.4 × 3.6 cm in size (MENOX EL2000, 
Kuraray Co. & Dainippon Ink and Chemicals Inc., 
Tokyo,  Japan) was used in this study.  The 
oxygenator consisted of double-layered polyoleﬁ n 
hollow ﬁ bers with a priming volume of 50 ml and a 
total membrane surface area of 0.4 m2,  having a low 
ﬂ ow resistance of 45 mmHg at a maximum blood ﬂ ow 
rate of 2.0 l/min (Kuraray Co.  Ltd.  internal 
technical manual).  The oxygenator was preprimed 
with heparinized crystalloid ﬂ uid (4 U/ml).
　　Pumpless ECMO circuit. 　Six infant mongrel 
dogs,  weighing 4.8 to 7.7 kg (mean weight,  6.5 kg), 
were used in the present study.  The animals were 
initially anesthetized by the intramuscular 
administration of ketamine hydrochloride (10 mg/kg) 
and atropine sulfate (0.025 mg/kg),  with additional 
intravenous thiopental sodium (10 mg/kg).  The 
animals were then intubated,  paralyzed with 
pancuronium bromide (2 mg),  and placed on a 
mechanical ventilator (Model 613,  Harvard 
Apparatus,  Holliston,  MA,  USA) at a respiratory 
rate of 15 bpm and a tidal volume of 20 ml/kg. 
Anesthesia was maintained with a mixture of 50ｵ 
oxygen,  50ｵ nitrous oxide,  and halothane (0.5ｵ). 
A femoral arterial line was established to measure 
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Fig. 1　　Schematic illustration of the experimental ECMO circuit.  PA,  pulmonary artery ; LA,  left atrium ; RV,  right ventricle.
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the arterial blood pressure and to draw blood 
samples.  A 5-Fr Swan-Ganz thermodilution-cardiac 
output catheter was also placed from the femoral 
vein into the PA for measurement of the mean 
pulmonary arterial pressure (MPAP ; mmHg),  mean 
right atrial pressure (MRAP ; mmHg),  and cardiac 
output (CO ; expressed as CI ; l/min/m2) as well as 
for drawing venous blood samples.
　　Left pneumonectomy was performed through a 
left fourth intercostal thoracotomy.  The oxygenator 
was placed in the bypass circuit between the left PA 
and LA using two 24-Fr cannulae after the intra-
venous administration of sodium heparin (200 U/kg) 
(Fig.  1).  Additional heparin was given as necessary 
to maintain the activated clotting time longer than 
400 sec.  The animals were supported without any 
inotropic agents throughout the experiments.
(1). Partial pulmonary bypass using an oxygen-
ator (partial pumpless ECMO support) : 　The 
partial pumpless ECMO support was commenced by 
opening the circuit,  with the native pulmonary circu-
lation preserved.  Anesthesia was changed from a mix-
ture of 50ｵ oxygen,  50ｵ nitrous oxide,  and halo-
thane (0.5ｵ) to room air and halothane (0.5ｵ) with 
the same mechanical ventilation set-up being pre-
served.  Pure oxygen was supplied to the membrane 
oxygenator with the gas blender at ﬂ ow rates of 1 to 
2 l/min,  and the sweep gas outﬂ ow port was brieﬂ y 
suctioned to prevent occlusion by condensation.  The 
animals were observed for a duration of 1 h.
(2). Total pulmonary bypass using an oxygenator 
(total pumpless ECMO support) : 　For the 
animals undergoing partial ECMO support,  the right 
PA was ligated to divert the right ventricular output 
to the device,  and a total PA-to-LA bypass driven by 
the RV alone was begun.  After ligating the right 
PA,  the gas anesthesia was changed to the 
intravenous administration of ketamine HCl (7.5 mg/
kg/h) and mechanical ventilation was discontinued by 
removing the endotracheal tube.  The incision was 
closed after 6 h,  and the hemodynamics and blood gas 
state were observed for a period of 12 h.  Each 
animal was euthanized by injecting a lethal dose of 
pentobarbital (80 mg/kg) intravenously after 
assessment.  A postmortem examination of the lungs 
in the animals and of the circuit in order to identify 
any thrombus was performed.
　　All animals received humane care in compliance 
with the “Guide for the Care and Use of Laboratory 
Animals” published by the National Institutes of 
Health (NIH publication No.  85ﾝ23,  revised 1985).
　　Data acquisition. 　Hemodynamic changes were 
studied by the indices of MRAP,  MPAP,  the mean 
arterial blood pressure (MABP ; mmHg),  and CO 
(CI).  The blood pressures as well as inlet and outlet 
pressures of the oxygenator were measured using a 
Polygraph 360 (NEC Co.,  Tokyo,  Japan),  and CO 
was measured by the thermodilution method using a 
Cardiac Output Monitor with a Printer (COM-
 2P-100,  Baxter Healthcare Co.,  Irvine,  CA,  USA). 
A blood gas analysis,  expressed as oxygen (O2), 
saturation (ｵ) and arterial carbon dioxide tension 
(PaCO₂) with a hemoglobin measurement was carried 
out using a Blood Gas SystemTM (Ciba Corning 
Diagnostic Corp.,  Medﬁ eld,  MA,  USA).  To examine 
the oxygenator performance,  the rate of blood ﬂ ow 
through the oxygenator (device blood ﬂ ow : DBF ; ml/
min) was measured using an ultrasonic blood ﬂ ow 
meter (T201,  Transonic System Inc.,  Ithaca,  NY, 
USA).  The ﬂ ow resistance (mmHg/l/min) of the 
membrane oxygenator was calculated using these 
data.  To assess the O2 transfer of the oxygenator, 
the formula as described by Boonstra et al. [6] was 
used,  and the CO₂ transfer was determined from a 
Van Slyke nomogram [7].  The activated clotting 
time was measured with a blood coagulation timer 
(HemocronTM 400,  International Technidyne Co., 
Edison,  NJ,  USA).  All data were obtained at the 
following time points : before the bypass operation, 
at 1 h after the establishment of partial ECMO 
support,  and at 0.25,  0.5,  1,  2,  3,  4,  5,  6,  8,  10, 
and 12 h after ligation of the right PA.
　　Statistical analysis. 　Serial quantitative data 
were compared by nonparametric one-way repeated 
measures analysis of variance (ANOVA) to determine 
the eﬀ ect of the study group and time.  When the p 
ratio of the ANOVA was signiﬁ cant (p ＜ 0.05),  the 
diﬀ erences between the data at each time and those 
at baseline were tested by the paired 2-tailed t test. 
All data in the text,  tables,  and ﬁ gures are 
presented as the means ± the standard deviations.
Results
　　The pulmonary bypass circuit with an in-line 
oxygenator was successfully established in the 6 
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dogs,  all of which were available for analysis.  After 
the induction of partial ECMO support,  the averaged 
bypass blood ﬂ ow through the device and CO were 
332 ± 99 ml/min and 1062 ± 266 ml/min ; the 
averaged percentage of the device blood ﬂ ow rate in 
CO was 34 ± 16ｵ.  The MPAP increased 
signiﬁ cantly from 16.3 ± 4.7 mmHg before ECMO 
support to 19.7 ± 6.3 mmHg (p ＜ 0.05),  while the 
MRAP did not show signiﬁ cant change (Table 1). 
The MABP decreased from 100.7 ± 16.0 to 
89.5 ± 17.7 mmHg,  and the CI slightly decreased 
from 2.97 ± 0.36 to 2.75 ± 0.74 l/min/m² ; however 
these changes were not signiﬁ cant.  Arterial O₂ 
saturation and the PaCO₂ level did not show any 
remarkable change.
　　After the establishment of total pumpless ECMO 
support there were signiﬁ cant diﬀ erences (ANOVA) 
in hemodynamics with respect to the MABP,  MPAP, 
CI,  and hemoglobin value.  The MABP decreased 
from 100.7 ± 16.0 mmHg before ECMO to 66.0 ± 13.0 
(p ＜ 0.005),  62.8 ± 16.9 (p ＜ 0.05),  62.8 ± 15.1 mmHg 
(p ＜ 0.005),  and 46.0 ± 15.1 mmHg (p ＜ 0.001) at 1 h, 
4 h,  8 h and 12 h,  respectively.  The MPAP 
increased from 16.3 ± 4.7 mmHg before ECMO to 
32.8 ± 9.3 (p ＜ 0.05),  27.0 ± 7.2 (p ＜ 0.05), 
26.2 ± 6.0 mmHg (p ＜0 .05),  and 22.8 ± 6.7 mmHg (not 
signiﬁ cant) at 1 h,  4 h,  8 h and 12 h,  respectively. 
The MRAP remained relatively stable but was on an 
increasing trend.  The CI showed a signiﬁ cant 
decrease from 2.97 ± 0.36 l/min/m² before ECMO to 
1.65 ± 0.22 l/min/m² at 1 h (p ＜ 0.005) and to 
1.26 ± 0.21 l/min/m² at 12 h (p ＜ 0.001).  The 
hemoglobin value decreased from 12.0 ± 2.1 g/dl 
before ECMO to 9.1 ± 3.6 g/dl at 12 h.  However, 
blood gas analysis revealed that the arterial O₂ 
saturation and PaCO₂ levels were suﬃ  ciently 
maintained throughout the experiment,  presenting a 
mean O₂ transfer rate of 42.1 ± 11.2 ml/min and a 
CO₂ transfer rate of 37.4 ± 11.2 ml/min with a mean 
blood ﬂ ow rate of 500 ± 142 ml/min.  There were no 
signiﬁ cant diﬀ erences (ANOVA) in the O₂ transfer 
rate,  CO₂ transfer rate,  and ﬂ ow resistance data 
over the duration of the total pumpless ECMO 
support (Table 2).  The average ﬂ ow resistance of 
the membrane oxygenator in the total ECMO support 
was calculated to be 25.2 ± 9.5 mmHg/l/min. 
Thrombogenesis within the membrane oxygenator 
was observed in 2 of the 6 cases,  and the membrane 
oxygenator was noted to resister increased mean ﬂ ow 
resistance at the maximums of 40.4 mmHg/l/min and 
41.7 mmHg/l/min in total ECMO support, 
respectively.  In these cases,  the blood ﬂ ow rates 
through the device were as low as 250 ml/min and 
230 ml/min in partial ECMO support respectively, 
and both air embolus and macroscopic thrombus were 
noted inside the membrane oxygenator.  No plasma 
leakage of the oxygenator was observed.  A 
postmortem examination of the lungs in the 6 animals 
revealed no macroscopic thrombus in the pulmonary 
vascular system.
Discussion
　　Two types of implantable artiﬁ cial lungs have 
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Table 1　　Data from pumpless ECMO support
Variable
Before
ECMO
(n=6)
Partial
ECMO
(n=6)
Total ECMO
1 h
(n=6)
4 h
(n=6)
8 h
(n=6)
12 h
(n=6)
MABP (mmHg) 100.7 ± 16.0 89.5 ± 17.7  66.0 ± 13.0† 62.8 ± 16.9* 62.8 ± 15.1† 46.0 ± 15.1††
MPAP (mmHg) 16.3 ± 4.7 19.7± 6.3*  32.8 ± 9.3*  27.0± 7.2* 26.2 ± 6.0*  22.8 ± 6.7
MRAP (mmHg)  4.0 ± 1.1 5.0 ± 2.3  5.7 ± 1.6  5.5 ± 0.8 6.0 ± 1.3  6.5 ± 2.2
Cadiac Index (l/min/m2)  2.97 ± 0.36 2.75 ± 0.74  1.65 ± 0.22†  1.41 ± 0.20†† 1.48 ± 0.39† 1.26 ± 0.21††
Hemoglobin (g/dl) 12.0 ± 2.1 11.7 ± 3.4  12.2 ± 3.3  11.5 ± 3.1 9.7 ± 3.4  9.1 ± 3.6
SaO2 (%) 99.6 ± 0.2 99.6 ± 0.5  99.8 ± 0.1  99.8 ± 0.2 99.7 ± 0.3  99.7 ± 0.2
PaCO2 (mmHg) 27.7 ± 6.3 2.8 ± 6.2  26.3 ± 9.0  31.2 ± 9.3 33.5 ± 14.1  42.5 ± 20.2
Data are means ± standard deviations.  Signiﬁ cance : *p＜0.05,  **p＜0.01,  †p＜0.005,  ††p＜0.001 versus each baseline before 
ECMO.  MABP,  mean arterial blood pressure : MPAP,  mean pulmonary arterial pressure : MRAP,  mean roght atrial pressure : SaO2,  
arterial oxygen saturation ; PaCO2,  arterial carbon dioxide tension.
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been developed,  an intravenous membrane oxygenator 
type and an intrathoracic artiﬁ cial lung type [5,  8]. 
The pumpless ECMO system used in the present 
study was one of the latter types,  which has the 
advantage of suﬃ  cient gas exchange.  Patients would 
have no limitation of daily activities if an 
intrathoracic implantable artiﬁ cial lung could be 
clinically used in the future.  However,  this type has 
shortcomings,  in that a thoracotomy is a necessity 
and bleeding due to heparinization can occur.  In 
cases with a functional disorder such as a decline in 
the gas exchange performance,  thrombogenesis,  and 
air thrombus in the device,  it would be better to 
keep the artiﬁ cial lung out of the pleural cavity 
rather than to implant the whole device into the 
pleural cavity,  so as to be able to immediately 
exchange a malfunctioning artiﬁ cial lung.  Thus,  the 
artiﬁ cial lung was positioned paracorporeally in the 
present experiment.
　　Regarding the experimental preparations, 
cannulation was used for blood access in the canine 
model because we had observed gradual bleeding at 
the anastomotic sites between the left PA and 
expanded polytetrafluoroethylene graft in our 
preliminary study.  The membrane oxygenator used 
in the present study was MENOXTM EL2000,  and its 
expected pressure drop at a ﬂ ow rate of 1 l/min, 
which was considered to correspond to a cardiac 
index of more than 2 l/min/m² for such small animals, 
was calculated to be about 24 mmHg (Kuraray Co. 
Ltd.  internal technical manual).  Therefore,  we 
thought that the RV with a MPAP higher than 
24 mmHg could perfuse the membrane oxygenator 
without causing the development of a low cardiac 
output syndrome.
　　After induction of a partial bypass,  approximately 
one-third of the RV output was passively shunted 
through the bypass circuit,  and the MPAP increased 
signiﬁ cantly.  However,  marked cardiac dysfunction 
resulting from increased afterload was not observed. 
The MABP,  MRAP,  and cardiac index did not show 
signiﬁ cant change,  and the gas exchange was 
suﬃ  cient for the body.
　　The animals were able to tolerate the acute 
excessive pressure overload by ligation of the right 
PA.  The membrane oxygenator was able to supply 
O₂ and CO₂ at average gas transfer rates greater 
than 30 ml/min with a small membrane surface area 
of 0.4 m² during the bypass and provided suﬃ  cient 
gas exchange for the body.  These results are similar 
to those reported by Cook et al.  [9] and Vaslef et al. 
[10] for their prototypes of implantable artiﬁ cial 
lungs.  After ligation of the right PA,  the animals 
sustained with stable blood gas data,  but cardiac 
failure persisted during the duration of total ECMO 
support.  Although we hypothesized that the RV 
pressure would help to drive the artiﬁ cial lung 
without causing low output syndrome by means of a 
bypass from the PA to LA with an in-line membrane 
oxygenator,  the animals showed remarkable 
impairment in cardiac function in response to the 
total pumpless ECMO.  These results suggest that 
the ﬂ ow resistance of the membrane oxygenator was 
still too high for use in a total pumpless ECMO.  A 
reduction in the resistance of an artiﬁ cial lung is 
necessary to obtain a high enough device blood ﬂ ow 
rate without impairing cardiac function,  while the 
ﬂ ow resistance is reported to be high in current 
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Table 2　　Gas exchange performance of the device
Variable
Partial
ECMO
(n=6)
Total ECMO
1 h
(n=6)
4 h
(n=6)
8 h
(n=6)
12 h
(n=6)
VO2 (ml/min) 27.6 ± 7.2 45.5 ± 10.5 42.6 ± 9.0 42.8 ± 10.9 34.1 ± 14.3
VCO2 (ml/min) 36.7 ± 20.3 42.7 ± 11.2 38.2 ± 14.9 40.7 ±13.2 36.3 ± 11.4
DBF (ml/min) 332 ± 99 555 ± 81 475 ± 102 491 ± 134 397 ± 87*
DFR (mmHg/l/min) 17.0 ± 12.4 26.8 ± 7.8 26.6 ± 8.7 23.1 ± 11.0 24.1 ± 10.8
Data are means ± standard deviations.  Signiﬁ cance : *p＜0.05,  versus baseline 1 h after induction of total ECMO.  VO2,  oxygen 
transfer rate of the membrane oxygenator ; VCO2,  carbon dioxide transfer rate of the membrane oxygenator ; DBF,  device blood 
flow ; DFR,  device flow resistance.
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membrane oxygenators as well as in our device [11, 
12].  There have been several reports on development 
of low pressure-loss implantable artiﬁ cial lungs in 
which the values of resistance were 3.5 mmHg/l/min 
and 2.5 mmHg/l/min [9,  13].  It is expected that a 
low pressure-loss implantable artiﬁ cial lung,  such as 
a device with a reduction in the hollow-ﬁ ber density, 
will be developed and become commercially available 
for use in total ECMO bypass surgery in the near 
future.  However,  clot formation and bubbling in the 
membrane oxygenator was observed in 2 of the 6 
cases,  in which the ﬂ ow resistance increased 
remarkably.  However,  the hemoglobin values showed 
a decreasing trend.  It is impossible to overlook the 
problem of bleeding due to heparinization for long-
term survival.  Determination of the optimum dose of 
heparin,  means of anticoagulation,  and regulation of 
sweep gas ﬂ ow seem to be necessary for preventing 
bleeding or clot formation.
　　From a clinical point of view,  diversion of the 
whole RV output to the device might have some 
shortcomings in the long term because a malfunctioning 
artiﬁ cial lung could be more easily changed with a 
partial bypass than with a total bypass.  Furthermore, 
lung function not only involves gas exchange but is 
also associated with immunity,  neuropeptide activity, 
and drug metabolism [14ﾝ16].  Accordingly,  a partial 
bypass is thought to function better physiologically 
than a total bypass.  Further investigation is needed 
to determine the eﬀ ects of a long-term bypass for a 
period of weeks or months.
　　Although the eﬀ ects of a long-term bypass need 
to be investigated,  the results suggest the possibility 
of a pumpless partial ECMO support between the 
PA and LA with a membrane oxygenator.  Low 
pressure-loss implantable artiﬁ cial lungs,  which 
enable placement of the device in the body,  are 
currently being developed [17,  18].  Further studies 
on the applicability of a pumpless implantable ECMO 
device should be conducted to determine whether a 
pumpless ECMO between the right heart and left 
heart is an eﬀ ective treatment modality or can be 
used as a bridge to lung transplantation in patients 
with end-stage pulmonary diseases.
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